📣 VC round data is live. Check it out!

Omnicell Valuation Multiples

Discover Omnicell's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like EverCommerce, Kusuri No Aoki, Dis-Chem Pharmacies, Qingdao Baheal Medical and more.

Omnicell Overview

About Omnicell

Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.


Founded

1992

HQ

United States

Employees

3.7K

Financials (LTM)

Revenue: $1B
EBITDA: $149M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Omnicell Financials

Omnicell reported last 12-month revenue of $1B and EBITDA of $149M.

In the same LTM period, Omnicell generated $576M in gross profit, $149M in EBITDA, and $81M in net income.

Revenue (LTM)


Omnicell P&L

In the most recent fiscal year, Omnicell reported revenue of $1B and EBITDA of $140M.

Omnicell is profitable as of last fiscal year, with gross margin of 42%, EBITDA margin of 12%, and net margin of 6%.

See analyst estimates for Omnicell
LTMLast FY202320242025202620272028
Revenue$1B$1B$1B$1B$1B
Gross Profit$576M$503M$497M$471M$503M
Gross Margin48%42%43%42%42%
EBITDA$149M$140M$61M$90M$92M
EBITDA Margin12%12%5%8%8%
EBIT Margin8%7%(3%)0%0%
Net Profit$81M$75M($20M)$13M$2M
Net Margin7%6%(2%)1%0%

Financial data powered by Morningstar, Inc.

Omnicell Stock Performance

Omnicell has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


Omnicell's stock price is $43.16.

Omnicell share price decreased by 2.2% in the last 30 days, and increased by 46.8% in the last year.

Omnicell has an EPS (earnings per share) of $1.65.

See more trading valuation data for Omnicell
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B-2.2%-2.2%29.3%46.8%$1.65

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Omnicell Valuation Multiples

Omnicell trades at 1.6x EV/Revenue multiple, and 12.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Omnicell

EV / Revenue (LTM)


Omnicell Financial Valuation Multiples

As of June 2, 2026, Omnicell has market cap of $2B and EV of $2B.

Omnicell has a P/E ratio of 24.3x.

LTMLast FY202320242025202620272028
EV/Revenue1.6x1.6x1.7x1.7x1.6x
EV/EBITDA12.8x13.7x31.5x21.2x20.8x
EV/EBIT20.5x22.7x(54.8x)n/mn/m
EV/Gross Profit3.3x3.8x3.8x4.1x3.8x
P/E24.3x26.1x(96.4x)156.6xn/m
EV/FCF-27.6x15.2x14.2x27.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Omnicell Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Omnicell Margins & Growth Rates

Omnicell grew revenue by 5% and EBITDA by 16% in the last fiscal year.

In the most recent fiscal year, Omnicell reported gross margin of 42%, EBITDA margin of 12%, and net margin of 6%.

See estimated margins and future growth rates for Omnicell

Omnicell Margins

Last FY202420252026202720282029
Gross Margin42%42%42%44%
EBITDA Margin12%8%8%13%
EBIT Margin7%0%0%8%
Net Margin6%1%0%7%
FCF Margin6%12%6%-

Omnicell Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%(3%)7%5%
Gross Profit Growth10%(5%)7%10%
EBITDA Growth16%48%2%77%
EBIT Growth25%(101%)1431%1950%
Net Profit Growth18%(162%)(84%)4223%
FCF Growth-7%(49%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Omnicell Operational KPIs

Omnicell's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Omnicell's Rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Omnicell's Rule of X is 26% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Omnicell
LTMLast FY202320242025202620272028
Rule of 4018%18%---
Bessemer Rule of X26%26%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.1M---
R&D Expenses to Revenue7%7%8%8%7%
Opex to Revenue-42%46%42%42%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
EverCommerce4.0x4.0x13.2x13.0x
Kusuri No Aoki0.8x0.7x9.7x10.4x
Dis-Chem Pharmacies0.8x0.8x11.0x10.6x
Qingdao Baheal Medical1.7x1.6x13.3x13.2x
Ebos Group0.4x0.4x9.2x8.0x
LBX Pharmacy0.5x0.5x4.8x5.2x
Selçuk Ecza0.3x0.2x10.6x7.1x
Create SD Holdings0.4x-6.3x-

This data is available for Pro users. Sign up to see all Omnicell competitors and their valuation data.

Start Free Trial

Acquisitions by Omnicell

Omnicell has acquired 5 companies to date.

Last acquisition by Omnicell was on January 4th 2022. Omnicell acquired MarketTouch Media for $82M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Omnicell

MarketTouch Media
ReCept Pharmacy
InPharmics
Ateb
Description
MarketTouch Media is an interactive technologies provider that streamlines and automates client communications for businesses. The company develops systems enabling organizations to manage and execute customer engagement campaigns more efficiently through automated workflows and digital communication tools.
ReCept Pharmacy is a Fort Worth-based pharmacy specializing in 340B program management and specialty pharmacy services within community settings. Founded in 1978, the company focuses on patient-centered care delivery for complex medication needs.
InPharmics is a St. Louis-based software provider of 340B compliance and medication cost analytics for U.S. hospital pharmacies. Its platform tracks drug diversion prevention, contract pharmacy management, and supply chain security under the Drug Supply Chain Security Act. Clients include community hospitals and health systems using tools for rebate optimization. Launched in 2008, InpPharmics integrates with Epic and Cerner EHRs.
Ateb is a pharmacy performance platform delivering patient care analytics for independent pharmacies. Headquartered in Athens, Georgia, the company provides MTM services, appointment scheduling via Patient Management Access Portal, and revenue optimization tools. Ateb integrates with EHR systems for 14,000 pharmacies, generating performance reports on immunization and diabetes management outcomes.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Houston, TX
Fort Worth, TX
Madison, WI
Raleigh, NC
Deal Date4 Jan 20222 Dec 202119 Apr 201729 Nov 2016
Valuation$82M$100Mundisclosed$41M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Omnicell acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Omnicell

When was Omnicell founded?Omnicell was founded in 1992.
Where is Omnicell headquartered?Omnicell is headquartered in United States.
How many employees does Omnicell have?As of today, Omnicell has over 3K employees.
Who is the CEO of Omnicell?Omnicell's CEO is Randall A. Lipps.
Is Omnicell publicly listed?Yes, Omnicell is a public company listed on Nasdaq.
What is the stock symbol of Omnicell?Omnicell trades under OMCL ticker.
When did Omnicell go public?Omnicell went public in 2001.
Who are competitors of Omnicell?Omnicell main competitors include EverCommerce, Kusuri No Aoki, Dis-Chem Pharmacies, Qingdao Baheal Medical, Ebos Group, LBX Pharmacy, Selçuk Ecza, Create SD Holdings, iFLYHealth, Indegene.
What is the current market cap of Omnicell?Omnicell's current market cap is $2B.
What is the current revenue of Omnicell?Omnicell's last 12 months revenue is $1B.
What is the current revenue growth of Omnicell?Omnicell revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Omnicell?Current revenue multiple of Omnicell is 1.6x.
What is the current EBITDA of Omnicell?Omnicell's last 12 months EBITDA is $149M.
What is Omnicell's EBITDA margin?Omnicell's last 12 months EBITDA margin is 12%.
What is the current EV/EBITDA multiple of Omnicell?Current EBITDA multiple of Omnicell is 12.8x.
How many companies Omnicell has acquired to date?As of June 2026, Omnicell has acquired 5 companies.
What was the largest acquisition by Omnicell?$275M acquisition of Aesynt on 29th October 2015 was the largest M&A Omnicell has done to date.
What companies Omnicell acquired?Omnicell acquired Aesynt, ReCept Pharmacy, MarketTouch Media, Ateb, and InPharmics.
In how many companies Omnicell has invested to date?Omnicell hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Omnicell

Lists including Omnicell

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial